

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Mouse monoclonal anti-CD163

RRID:AB_2756375

Type: Antibody

Proper Citation

Leica Biosystems Cat# NCL-L-CD163, RRID:AB_2756375

Antibody Information

URL: http://antibodyregistry.org/AB_2756375

Proper Citation: Leica Biosystems Cat# NCL-L-CD163, RRID:AB_2756375

Target Antigen: CD163

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: IHC

Antibody Name: Mouse monoclonal anti-CD163

Description: This monoclonal targets CD163

Target Organism: human

Clone ID: 10D6

Antibody ID: AB_2756375

Vendor: Leica Biosystems

Catalog Number: NCL-L-CD163

Record Creation Time: 20231110T033316+0000

Record Last Update: 20260829T002202+0000

Ratings and Alerts

No rating or validation information has been found for Mouse monoclonal anti-CD163.

No alerts have been found for Mouse monoclonal anti-CD163.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bernstein AJ, et al. (2026) Compartment-specific tumor-infiltrating immune cells and prognosis in breast cancer. *iScience*, 29(2), 114759.

Pham FK, et al. (2026) Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy. *Journal for immunotherapy of cancer*, 14(6).

Solomon BJ, et al. (2025) The Impact of the Tumor Microenvironment on the Effect of IL-1 ? Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. *Cancer research communications*, 5(4), 632.

Suzuki H, et al. (2025) GALNT7 Stratifies dMMR/MSI Colorectal Cancer into Distinct Molecular Subsets Associated with Prognosis and PD-L1 Expression. *Cancer research communications*, 5(9), 1530.

Fiore D, et al. (2025) A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities. *Cell reports. Medicine*, 6(4), 102029.

Trotta R, et al. (2025) Activated T Cells Break Tumor Immunosuppression by Macrophage Reeducation. *Cancer discovery*, 15(7), 1410.

Wu SG, et al. (2025) Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. *Clinical and translational medicine*, 15(1), e70149.

Marzano P, et al. (2025) Tissue-Specific Immunosuppressive and Proliferating Macrophages Fuel Early Metastatic Progression of Human Colorectal Cancer to the Liver. *Cancer immunology research*, 13(11), 1783.

Sahl RE, et al. (2024) Prolonged Endurance Exercise Increases Macrophage Content and Mitochondrial Respiration in Adipose Tissue in Trained Men. *The Journal of clinical endocrinology and metabolism*, 109(2), e799.

Koganemaru S, et al. (2024) The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer. *Cancer research communications*.

Roemer MGM, et al. (2023) Multi-scale spatial modeling of immune cell distributions enables survival prediction in primary central nervous system lymphoma. *iScience*, 26(8), 107331.

Liu X, et al. (2023) Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. *Cancer cell*, 41(6), 1073.

Biermann J, et al. (2022) Dissecting the treatment-naïve ecosystem of human melanoma brain metastasis. *Cell*, 185(14), 2591.

Wang LB, et al. (2021) Proteogenomic and metabolomic characterization of human glioblastoma. *Cancer cell*, 39(4), 509.

Dupont M, et al. (2020) Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages. *eLife*, 9.

Roy A, et al. (2020) Hippocampal granule cell dispersion: a non-specific finding in pediatric patients with no history of seizures. *Acta neuropathologica communications*, 8(1), 54.

Toulmonde M, et al. (2020) High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. *EBioMedicine*, 62, 103131.

Krug K, et al. (2020) Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. *Cell*, 183(5), 1436.

Gillette MA, et al. (2020) Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. *Cell*, 182(1), 200.

Souriant S, et al. (2019) Tuberculosis Exacerbates HIV-1 Infection through IL-10/STAT3-Dependent Tunneling Nanotube Formation in Macrophages. *Cell reports*, 26(13), 3586.